Skip to main navigation Skip to search Skip to main content

Progress of anti-tuberculosis drug targets and novel therapeutic strategies

  • Yang Zhang
  • , Ruiying Wu
  • , Mingrui Sun
  • , Xiaotian Li
  • , Ren Fang
  • , Jiayin Xing
  • , Zhaoli Li
  • , Yurong Wen
  • , Ningning Song
  • Shandong Second Medical University
  • Ltd.
  • The First Affiliated Hospital of Xi’an Jiaotong University

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Tuberculosis, a chronic infectious disease caused by Mycobacterium tuberculosis complex, has re-emerged as the leading cause of death worldwide as a single infectious agent. The increasing prevalence of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis poses a severe and growing threat to global health. Therefore, it is urgent to find new drug targets. Recently, significant advancements have been made in the research of drug targets and novel therapeutic strategies for tuberculosis. This review summarizes recent processes on anti-tuberculosis drug targets, such as cell wall synthesis, nucleic acid replication and transcription, energy metabolism, and ferroptosis. Furthermore, this review summarizes the research progress of three innovative tuberculosis treatment strategies, including antimicrobial peptides, host-directed therapies, and nanoparticle-based drug delivery systems, aiming to provide a theoretical foundation and new research perspectives for the clinical development of new drugs.

Original languageEnglish
Article number1637254
JournalFrontiers in Microbiology
Volume16
DOIs
StatePublished - 2025
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • anti-tuberculosis drugs
  • drug target
  • Mycobacterium tuberculosis
  • novel therapeutics
  • tuberculosis treatment

Fingerprint

Dive into the research topics of 'Progress of anti-tuberculosis drug targets and novel therapeutic strategies'. Together they form a unique fingerprint.

Cite this